Skip to main content

Table 2 Characteristics of ANCA-associated vasculitis patients who received rituximab for remission maintenance

From: Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab

Study place N Age Men PR3-ANCA CYC CYC RTX Kidney Lung Orb-Subg BVAS Time to RTX FU mo IgG before IgG after SI HypoG Ref
y % % % g g % % %   mo   g/L g/l % %
Nottingham, UK 11 41 64 100 100 NR 8 55 46 NR 14 72 32 NR NR NR 9 25
Paris 2011, France 28 51 60 68 100 48 NR 32 64 14 15 84 38 7.8 7.0 11 11 26
Rochester, US 53 46 47 98 100 NR NR 42 49 NR 5 120 53 8.4 5.7 NR NR 28
Freiburg, Germany 37 62 57 81 92 12 NR 60 81 NR 13 99 30 9.9 NR 16 27 24
Boston, US 172 60 45 43 NR NR NR 62 44 NR 2 NR 25 NR NR 15 10 29
Paris 2014, France 66 50 49 80 89 29 4.6 21 47 14 10 67 34 8.3 7.5 14 2 30
Uppsala, Sweden 12 NR 42 100 100 61 NR 50 100 42 9 35 79 8.5 6.8 33 NR 31
MC, France 80 53 NR 84 98 13 NR 55 71 10 7 54 18 NR NR 15 NR 32
Mainritsan, France 57 54 65 77 100 7.3 2.5 70 58 NR NR 3 28 6.1 6.9 19 NR 5
Cambridge, UK 69 52 41 74 91 13.5 6 12 29 12 NR 60 59 9.3 8.0 29 41 7
Tromsø, Norway 29 50 52 86 97 17 9 59 66 62 10 57 49 7.7 4.9 24 45 8
  1. BVAS Birmingham Vasculitis Activity Score, CYC cyclophosphamide, FU follow-up during maintenance remission with rituximab, HypoG rate of hypogammaglobulinemia, MC multicentric study, N number of patients, NR not reported, Orb-Subg frequency of orbital-subglottic involvement, RTX rituximab, Ref reference, SI rate of severe infection